ACC unveils 2013 late-breakers

The American College of Cardiology (ACC) has released its lineup of late-breaking clinical trials that will be featured at its 2013 annual scientific meeting, March 9 through 11 in San Francisco. Cardiovascular Business will be there to bring you daily coverage of the presentations.

The schedule includes:

March 9: Opening showcase and late-breaking clinical trials

  • Final results of Randomized Trial of Left Atrial Appendage Closure Versus Warfarin for Stroke/Thrombolembolic Prevention in Patients with Non-Valvular Atrial Fibrillation
  • HPS2-THRIVE: Randomized Comparison of  Extended Release Niacin/Laropiprant 2 g Daily Versus Placebo in 25,673 Patients at High Risk of Occlusive Vascular Events

March 10: Interventional

  • Early High Dose Rosuvastatin for Contrast-induced Nephropathy Prevention in Acute Coronary Syndrome
  • A Randomized Evaluation of the SAPIEN XT Transcatheter Valve System in Patients with Aortic Stenosis Who Are Not Candidates for Surgery: PARTNER 2, Cohort B Outcomes
  • One-Year Outcome of a Trial Comparing Second Generation Drug-eluting Stents Using Either Biodegradable Polymer of Durable Polymer: the NOBIRITM Biolimus-eluting vs. XIENCETM/PROMUSTM Everolimus-eluting Stent Trial (NEXT)
  • CHAMPION PHOENIX Trial, main results

March 10: Chronic CAD/stable ischemic heart disease and acute coronary syndromes

  • The STREAM Trial
  • Early Administration of Eplerenone in Patients with Acute MI Without Heart Failure: Results of the Randomized, Double-Blind, Placebo-Controlled REMINDER Trial
  • Effects of the P-Selectin Antagonist Inclacumab in the Select-Acute Coronary Syndrome Trial
  • Randomized Comparison of High-dose Oral Vitamins vs. Placebo in the Trial to Assess Chelation Therapy
  • Evaluation of Ranolazine in Patients with Type 2 Diabetes Mellitus and Chronic Stable Angina (TERISA): A Randomized Clinical Trial

March 11: General Cardiology

  • Three-year Outcomes after Transcatheter or Surgical Aortic Valve Replacement in High-Risk Patients with Severe Aortic Stenosis
  • A Randomized Trial to Compare Percutaneous Coronary Intervention Between Massachusetts Hospitals with Cardiac Surgery Onsite and Community Hospitals without Cardiac Surgery Onsite
  • The German Off-pump Coronary Artery Bypass Grafting in Elderly Patients (GOPCABE) Study
  • CORONARY: The CABG Surgery Off or On Pump Revascularization Study, One-year Results
  • PRAGUE-6 Trial: Off-pump Versus On-pump Coronary Artery Bypass Graft Surgery in Patients with EuroSCORE equal to or greater than 6

March 11: Heart Failure

  • The St. Vincent’s Screening to Prevent Heart Failure Study: Impact of Natriuretic Peptide Guided Screening and Treatment on Long-term Prevalence of Left Ventricular Dysfunction, Heart Failure and Cardiovascular Events
  • Digoxin Reduces 30-day All-cause Hospital Admission in Ambulatory Older Patients with Chronic Heart Failure and Reduced Ejection Fraction
  • The ASTRONAUT study: Aliskiren Trial on Acute Heart Failure outcomes
  • Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX) Trial

Around the web

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.